Can DRL’s new product launches offset the slowdown in Revlimid sales ?
Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with (...)
Site référencé: The Economic Times
The Economic Times
India’s evolving startup funding landscape : Nithin Kamath reflects on VC growth and entrepreneurial momentum
24/10/2025
How Shankar Sharma's house help bought Mumbai apartment without investing in stocks
24/10/2025
Paytm and Vedanta emerge as top buys amid sectoral rotation and profit booking : CA Rudramurthy BV
24/10/2025
$7 billion deals in banks, NBFCs in 2025. Sign of banking reforms ahead ?
24/10/2025
Ashish Kacholia-backed stock surges 26% in 5 sessions. What’s fuelling the rally today ?
24/10/2025
Geoff Dennis on sanctions, oil shock and India’s emerging market outlook
24/10/2025
